Who are Luspatercept Injection [Reblozyl]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Reblozyl, REBLOZYL, Luspatercept Injectable Product.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/luspatercept-injection-reblozyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Luspatercept Injection [Reblozyl] — Competitive Intelligence Brief

Luspatercept Injection [Reblozyl] (Luspatercept Injection [Reblozyl]) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythroid maturation agent. Area: Oncology.

phase 2 Erythroid maturation agent TGF-β superfamily ligands (GDF11, activin A) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Luspatercept Injection [Reblozyl] (Luspatercept Injection [Reblozyl]) — Groupe Francophone des Myelodysplasies. Luspatercept is a recombinant fusion protein that acts as a ligand trap for members of the TGF-β superfamily, modulating Smad2/3 signaling to enhance erythroid maturation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Luspatercept Injection [Reblozyl] TARGET	Luspatercept Injection [Reblozyl]	Groupe Francophone des Myelodysplasies	phase 2	Erythroid maturation agent	TGF-β superfamily ligands (GDF11, activin A)
Reblozyl	LUSPATERCEPT	Celgene Corp	marketed	Erythroid Maturation Agent [EPC]	Growth/differentiation factor 11	2019-01-01
REBLOZYL	LUSPATERCEPT-AAMT	CELGENE CORP	marketed	Erythroid Maturation Agent [EPC]	Growth/differentiation factor 11, Growth/differentiation factor 8
Luspatercept Injectable Product	Luspatercept Injectable Product	Sun Yat-sen University	marketed	Erythroid maturation agent	Activin A; TGF-β superfamily ligands

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythroid maturation agent class)

Groupe Francophone des Myelodysplasies · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Luspatercept Injection [Reblozyl] — Competitive Intelligence Brief. https://druglandscape.com/ci/luspatercept-injection-reblozyl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab